Alteration of adenomatous polyposis coli (APC)is
Aberrant crypt foci (ACF) are generally considered to be putative preneoplastic lesions for colorectal carcinomas in man 1) as well as in experimental animals.
2) Molecular analysis has revealed alteration of the adenomatous polyposis coli (APC)/β-catenin pathway to be one of the earliest events in colorectal carcinoma development, 3) being found in dysplastic ACF. 4, 5) In colon cancers with wildtype APC, 6) β-catenin may harbor mutations in exon 3, where serine and threonine residues are physiologically phosphorylated by glycogen synthase kinase (GSK)-3β. Mutations of serine/threonine residues prevent degradation of β-catenin protein in an APC-dependent manner 6) and cause activation of the β-catenin/Tcf-4 signal transduction pathway. 6, 7) In a rodent model, Takahashi et al. 8) found frequent mutations (6 of 8, 75%) in β-catenin exon 3 in azoxymethane (AOM)-induced rat colon adenocarcinomas. Furthermore, Dashwood et al. 9) demonstrated, although the number of samples was limited, all of 5 colon adenocarcinomas induced by 2-amino-3-methylimidazo [4,5- f]quinoline (IQ) and 4 of 7 (57%) by 2-amino-1-methyl-6-phenylimidazo- [4,5-b] pyridine (PhIP) to have mutations in exon 3. While Kakiuchi et al. 10) reported Apc to exhibit a specific onebase deletion in PhIP-induced rat colon carcinomas, these tumors did not have Apc mutations and it was concluded that Apc and β-catenin mutations are mutually exclusive. Suzui et al. 11) recently reported frequent (18 of 20, 90%) β-catenin mutations in colon cancers induced by methylazoxymethanol acetate plus 1-hydroxyanthraquinone.
However, the situation with regard to earlier lesions such as ACF, in which APC changes are believed to be involved in human cases, 12) remains unclear. Recent evidence suggests that β-catenin mutations are more frequent in small benign lesions than in large adenomas and invasive carcinomas, 13) so that adenomas in some cases may be end points in themselves. We recently analyzed the morphology and localization of ACF, adenomas and adenocarcinomas sequentially in PhIP-treated F344 rats and obtained a sufficient number of samples for statistical analysis. 14) PhIP is the most abundant heterocyclic amine in the human environment, 15) being produced in broiled meat and fish during cooking, 16) and is considered one of the most important carcinogens taken in the daily diet. We here utilized the same samples (46 ACF, 7 adenomas and 12 adenocarcinomas) to evaluate the importance of β-catenin mutations during the progression of ACF through to adenocarcinomas. The findings indicate that β-catenin gene mutations may occur early in ACF but that adenomas exhibit a higher frequency of this genetic alteration than adenocarcinomas.
MATERIALS AND METHODS
Sample and DNA isolation Three-week-old male Fischer 344 rats were treated with PhIP⋅HCl (Nard Institute, Osaka) as recently reported. 14) ACF were isolated and DNAs were extracted with InstaGene Purification matrix (BIO-RAD, Hercules, CA). Colon tumors appearing at weeks 50 and 75 were cut into two pieces. One half of each was histologically analyzed for classification into adenomas and adenocarcinomas as described.
14) The other was employed for DNA isolation with a QIAamp Tissue Kit (QIAGEN Co., Ltd., Tokyo). PCR-single strand conformation polymorphism (SSCP) analysis PCR-SSCP analysis was performed basically as described. 17) For the PCR, a 5 µl reaction mixture was used containing 1 µl of genomic DNA, 200 nM each of 5′ and 3′ primers, 200 µM each dNTP, 167 nM [α 32 P]dCTP (NEG-513H, NEN Life Science Products, Boston, MA), 0.025 units/µl AmpliTaq Gold DNA polymerase and its provided buffer (Perkin-Elmer, Applied Biosystems Division, Foster City, CA). The 5′-and 3′-primer sequences for amplification of the GSK-3β phosphorylation consensus sequence in exon 3 of β-catenin gene were 5′-GCTGAC-CTGATGGAGTTGGA-3′ (B1U) and 5′-GCTACTTGC-TCTTGCGTGAA-3′ (B1D), respectively.
8)
The PCR for tumor DNA samples was run as follows: 95°C-10 min ×1, 94°C-1 min: 55°C-1 min: 72°C-1 min ×30, 72°C-10 min ×1 with a PCR Thermal Cycler MP (TaKaRa, Ohtsu). For ACF, the cycle number was 35 instead of 30 to obtain a comparable sensitivity. Fivemicroliter aliquots of PCR products were diluted with 40 µl of loading dye (95% formamide, 20 mM EDTA, 10 mM NaOH, 0.25% bromophenol blue, and 0.25% xylene cyanol FF), denatured at 90°C for 5 min and chilled quickly on ice. Then the samples were electrophoretically separated in a 0.5× nondenaturing MDE polyacrylamide gel (FMC BioProducts, Rockland, ME) containing 5% glycerol at 40 W for 6 h using a power supply (Power Pac 3000, BIO-RAD) with a temperature probe set at 20°C in a cold room, dried, and applied to an imaging plate, which was then analyzed with a BAS 2500 (Fuji Film, Kanagawa).
Mutant controls for SSCP analysis of β-catenin, designated as M1 and M2 ( Fig. 1) , had a GAT-to-AAT mutation at codon 32 and a GGA-to-GAA mutation at codon 34, respectively, as reported.
Direct sequencing Sequencing was performed using an AmpliCycle Sequencing Kit (Perkin-Elmer) as described previously. 18) Briefly, SSCP bands of interest in polyacrylamide gels were excised, and DNA was eluted in 50 µl of 10 mM Tris-HCl, pH 8.0 at 50°C for 30 min. PCR was performed with 10 µl of the eluted DNAs or the original tumor DNAs, purified with a QIAquick PCR purification kit (QIAGEN Co., Ltd.), and used as templates for the following sequencing reaction. The primer B1U for β-catenin was end-labeled with [γ 32 P]ATP (NEN) by T4 polynucleotide kinase (New England Biolab, Beverly, MA) and the sequencing reaction was performed as follows: 95°C-2 min ×1, 95°C-1 min: 55°C-1 min: 72°C-1 min ×30 with PCR Thermal Cycler MP (TaKaRa). This was stopped with Stop Solution (provided by the manufacturer), then the heat-denatured samples were electrophoresed in 6% Long Ranger gel solution (FMC BioProducts) containing 7 M urea, dried, and exposed to imaging plates for analysis with the BAS 2500 (Fuji Film). #1 had a GAT-to-AAT mutation at codon 32. Tumors #2, 8 and 12 had GGA-to-GTA mutations at codon 34, #4 and 5 had GAT-to-GCT mutations at codon 32, and #3, 6, 7, 9, 10 and 11 were wild type. B, ACF #7 had a TCC-to-TAC mutation at codon 45, #9 had a GAT-to-TAT mutation at codon 56, #11 had a GGA-to-GTA mutation at codon 34, and #12 through 14 had GGA-to-GAA mutations at codon 34. N, normal control; M1 and M2, mutant controls harboring a GAT-to-AAT mutation in codon 32 and a GGA-to-GAA mutation in codon 34, respectively.
Statistical analysis
harboring mutations of β-catenin, with 95% confidence intervals obtained by the exact method, 19) were compared with the use of Fisher's exact probability method, as described elsewhere. 19) RESULTS β β β β-Catenin gene mutations in tumors Representative PCR-SSCP results are shown in Fig. 1A , tumors #4, 5, and 8 being adenomas and #1, 2, 3, 6, 7, 9, 10, 11, and 12 being adenocarcinomas. All of 7 adenomas (100%) were revealed to have mutations restricted to codons 32 and 34 (gray cells in the top panel of Fig. 2) . In codon 32, the mutations found were GAT (Asp) to GCT (Ala) (see tumors #4 and 5). In codon 34, they were GGA (Gly) to GAA (Glu) and to GTA (Val) as shown in tumor #8. In contrast to adenomas, only 6 out of 12 carcinomas (50%) harbored β-catenin mutations, found in codons 32 through 34, including GAT (Asp) to AAT (Asn) at codon 32 like tumor #1, TCT (Ser) to TGT (Cys) at codon 33, and GGA (Gly) to GTA (Val) as in tumors #2 and 12 and to GAA (Glu) (black cells in the top panel of Fig. 2 ). Summarizing the types of mutations, 6 were G:C-to-A:T transition mutations and 7 were transversions, including 2 A:T to C:G, 1 C:G to G:C, and 4 G:C to T:A. The remaining carcinomas like tumors #3, 6, 7, 9, 10, and 11 in Fig. 1A , migrating like the wild-type control (lane N), were confirmed to be wild type by sequencing analysis. β β β β-Catenin gene mutations in ACF ACF could be microscopically isolated without contamination with surrounding cells. 14) Genomic DNAs were successfully isolated with InstaGene Purification Matrix (BIO-RAD) and analyzed with PCR-SSCP (see Fig. 1B Comparison of frequency of β β β β-catenin gene mutations in ACF, adenomas and adenocarcinomas The mutation frequencies were 14 out of 46 (30.4%) in ACF, 7/7 (100%) in adenomas, and 6/12 (50%) in adenocarcinomas (shown in Fig. 3 , mean±95% confidence intervals). Statistical analysis (Fisher's exact probability method) revealed significant differences between ACF and adenomas (P<0.001) and between adenomas and adenocarcinomas (P<0.05) in β-catenin mutation rates.
DISCUSSION
We have recently reported a sequential study of PhIPinduced ACF, adenomas and adenocarcinomas in terms of morphology and localization in the rat large intestine using a crypt isolation technique.
14) The advantage of crypt isolation is in eliminating contamination with surrounding normal crypts as well as pericryptal stromal and inflammatory cells. Furthermore, single colonic crypts can be used as a maximum monoclonal unit for molecular analysis, as proved by our previous study of C3H↔BALB/c chimeric mice. 20) In the present case, we demonstrated more frequent β-catenin gene mutation in adenomas than in ACF and adenocarcinomas in the large intestine of PhIP-treated F344 rats.
In rat models, β-catenin mutations have been reported in colon tumors induced by azoxymethane, 8) heterocyclic amines 9) and methylazoxymethanol acetate plus 1-hydroxyanthraquinone. 11) Mutations were found in codons 33, 37, and 41 encoding serine and threonine that are direct targets for phosphorylation by GSK-3β. Also reported were alterations of codons 32, 34, and 35, encoding neighboring serine and threonine residues, possibly resulting in conformational changes and abnormal phosphorylation of β-catenin protein. In the present study, mutations were present in codons 32 through 34 in adenomas and adenocarcinomas, in accordance with the previous reports. 8, 9, 11) Our data suggest the possibility that specific mutations found in adenomas vs. adenocarcinomas could be correlated with the degree of degradation of β-catenin protein and consequently the transformation capability. Ten out of 13 changes involved guanine, consistent with a previous report that PhIP preferentially forms DNA adducts at guanines. 21) ACF are considered to be precancerous lesions because of their correlation with carcinogen exposure in animal models. 22) Dysplastic ACF are also thought to be precursors of human colorectal carcinomas. 12) In the present study, mutations were found in 30.4% (14 out of 46). Most (11 out of 14, 78.6%) were in codon 34, and involved guanine, as in adenomas/adenocarcinomas. While mutations in codons 47 and 56 have not been reported earlier to our knowledge, crypt cells could be transformed by an amino acid substitution of serine at codon 47, which might be an additional phosphorylation site, and the GAT (Asp)-to-TAT (Tyr) change at codon 56 could activate the β-catenin/Tcf signal transduction pathway by influencing phosphorylation or degradation by altering the complex tertiary structure.
Our finding that the β-catenin mutation rate was significantly higher in adenomas than in ACF (P<0.001) or adenocarcinomas (P<0.05) is consistent with the data of Samowitz et al., 13) showing a greater frequency in small colorectal adenomas than in larger adenomas and invasive carcinomas isolated from human patients. However, Suzui et al. 11) found 3 of 4 adenomas (75%) but 15 of 16 adenocarcinomas (94%) to harbor β-catenin mutations. This discrepancy may be explained by the difference in initiating carcinogen, methylazoxymethanol acetate being applied in combination with 1-hydroxyanthraquinone in their study. We used PhIP, one of the heterocyclic amines, since it is contained in the diet, 16) and this may better mimic the human case.
In conclusion, β-catenin mutations occurred in ACF and the existence of the same mutations in adenomas and adenocarcinomas suggests that they are early events during colorectal tumorigenesis. Various mutations, however, might have limited transforming potential as indicated by the findings (i) that some mutations in ACF were not found in tumors and (ii) that adenomas harbored β-catenin mutations more commonly than adenocarcinomas did. An explanation of this phenomenon requires further analysis of the transforming potential of individual β-catenin mutations. 
